Biogen Expands Neurological Pipeline

After shedding about 17 early-stage drug projects and its oncology and cardiovascular programs a few years ago, Biogen Idec seeks to gradually rebuild it early-stage drug pipeline with compounds aimed to treat neurological and autoimmune conditions. The company‚Äôs CEO talks to the Wall Street Journal about looking for new potential drugs for the company’s pipeline and discusses their late stage ALS and spinal muscular atrophy drugs.

Click here to read more.

Share this: